Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine (CC-486) Plus R-CHOP in High Risk DLBCL or Grade 3B FL
NCT02343536Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-486 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose at 1 year, Maximal Administered Dose at 1 year and 1 more. Started Apr 2015; status: completed.
02
Drugs
CC-486
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02343536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343536.